Trials / Approved For Marketing
Approved For MarketingNCT06132191
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Provide expanded access of cemiplimab in patients with solid tumors
Detailed description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.
Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Basal Cell Carcinoma (BCC)
- Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cemiplimab |
Timeline
- First posted
- 2023-11-15
- Last updated
- 2025-11-20
Source: ClinicalTrials.gov record NCT06132191. Inclusion in this directory is not an endorsement.